www.theguardian.com/society/2021/nov/15/uk-firm-to-trial-... An Oxfordshire-based company will soon start clinical trials of a second-generation vaccine against Covid-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines.
Emergex Vaccines has obtained regulatory approvals to commence the Phase I clinical trial of its Covid-19 vaccine candidate.
The double-blind, randomised, comparator-controlled trial will analyse the safety and tolerability of high and low doses of the vaccine.
To be conducted by the University of Lausanne, Switzerland Center for Primary Care and Public Health professor Blaise Genton, the trial will enrol a total of 13 subjects into two groups.
The company expects to dose the first subject with the first dose of the vaccine in January 2022.
Apart from safety and tolerability, the trial will offer information on CD8+ T-Cell-facilitated immune responses as a measure of protection against SARS-CoV-2 infection.
Emergex Vaccines chief commercial officer Robin Cohen said: “Our T Cell priming vaccines may offer significant benefits over current Covid-19 vaccines, including longer-lasting immunity and broader protection against new variants.
“We are proud to announce the initiation of this trial and look forward to gathering data to support the development of this important next-generation vaccine.”
The company is currently carrying out another Phase I trial of its dengue vaccine candidate in Switzerland.
report post quote code quick quote reply
+1-0Informative x 1
back to top
Actions are judged by intentions, so each man will have what he intended. ابو محمد
This cannot be undone and I am sure it will be greatly appreciated.
We apologise but you have been denied access to report posts in this thread. This could be due to excessively reporting posts and not understanding our forum rules. For assistance or information, please use the forum help thread to request more information. Jazakallah